The prevalence of autism spectrum disorder (ASD) among children in the United States has risen dramatically over the past two decades. In 2022, an estimated 32.2 out of every 1,000 8-year-old children were identified with ASD, marking a nearly fivefold increase from the rate of 6.7 per 1,000 children in 2000. This significant upward trend underscores the growing importance of understanding and addressing ASD in American society. Gender disparities in autism diagnosis The increase in ASD prevalence is not uniform across genders. From 2016 to 2019, male children were nearly four times more likely to be diagnosed with ASD than their female counterparts. Approximately 4.8 percent of boys aged 3 to 17 years had received an ASD diagnosis at some point in their lives, compared to only 1.3 percent of girls in the same age group. This substantial gender gap highlights the need for further research into potential biological and social factors influencing ASD diagnosis rates. Racial and ethnic variations in autism prevalence Autism prevalence also varies across racial and ethnic groups. Data from 2016 to 2019 show that non-Hispanic white children aged 3 to 17 years had an ASD prevalence of 2.9 percent, while around 3.5 percent of Hispanic children had ASD. While this statistic provides insight, it is essential to consider potential disparities in diagnosis and access to services among different racial and ethnic communities. Further research and targeted interventions may be necessary to ensure equitable identification and support for children with ASD across all populations.

These statistics present a group of measures on waiting times for autism spectrum disorder diagnostic pathways, based on the time between a referral for suspected autism and the first care contact associated with that referral. There are also multiple breakdowns based on the progression and outcomes of those referrals. Each of these measures contributes to an overall picture of waiting times for diagnostic pathways. The approach is outlined in the methodology section of this publication.

The prevalence rate of autism spectrum disorder among children aged eight years in the state Georgia was estimated to be around **** per 1,000 children. Autism spectrum disorder is a developmental disability characterized by deficits in social communication and interaction as well as repetitive behavior, interest, or activity patterns. Autism spectrum disorder in childrenAmong 14 U.S. states with areas that were monitored for autism spectrum disorder in 2022, California had the highest prevalence rates of autism spectrum disorder (ASD) among children aged eight years. In 2022, California’s prevalence rate was estimated to be **** cases per 1,000 children, while the rate was about **** cases per 1,000 children in Indiana. ASD is more common among male than female children, with an estimated ** male cases per 1,000 children and ** female cases per 1,000 children in California in 2022. Limitations in a child with autism can vary between individuals and develop over time. In California, the median age of diagnosis among children with an ASD diagnosis with an IQ greater than 70 was ********* of age, in comparison to ********* for children with an ASD diagnosis and an IQ less than or equal to 70, indicating a co-occurring intellectual disability. The prevalence of ASD has increased significantly since the late 1960s by about ** to ** times. Many studies suggest that this is due to improved awareness and recognition, as well as diagnostic capabilities. Autism is likely caused by a combination of genetics and environmental factors, where people with ASD may have abnormal levels of brain serotonin, which could disrupt early brain development.

This data table provides a collection of information from peer-reviewed autism prevalence studies. Information reported from each study includes the autism prevalence estimate and additional study characteristics (e.g., case ascertainment and criteria). A PubMed search was conducted to identify studies published at any time through September 2020 using the search terms: autism (title/abstract) OR autistic (title/abstract) AND prevalence (title/abstract). Data were abstracted and included if the study fulfilled the following criteria: • The study was published in English; • The study produced at least one autism prevalence estimate; and • The study was population-based (any age range) within a defined geographic area.

These statistics present the number of new referrals to mental health services for which the referral reason was suspected autism, as well as their waiting times to first appointment. These are Experimental Statistics and are being published to involve users and stakeholders in their development and as a means to build in quality at an early stage. This publication presents a partial picture of autism as assessments for autism may be undertaken in a variety of care settings. We are working closely with the Autism programme at NHS England to understand how this activity should flow across our mental health and community data sets and how to continue the development of this national reporting.

The prevalence rate of autism spectrum disorder among male children aged eight years in Georgia was estimated to be around ** per 1,000 children as of 2022. Autism spectrum disorder is a developmental disability characterized by deficits in social communication and interaction as well as repetitive behavior, interest, or activity patterns. This statistic displays the estimated prevalence of autism spectrum disorder among children aged 8 years in select U.S. states in 2022, by gender.

This statistic shows the estimated prevalence of autism spectrum disorder among children aged 3 to 17 years in the U.S. from 2016 to 2019, by gender. In that period, around 4.8 percent of male children and 1.3 percent of female children had been diagnosed with autism spectrum disorder at some point in their life.

This table provides county-level prevalence for 2018 for seven US states using linked statewide health and education data. For full methods see: Shaw KA, Williams S, Hughes MM, Warren Z, Bakian AV, Durkin MS, et al. Statewide county-level autism spectrum disorder prevalence estimates — seven U.S. states, 2018. Annals of Epidemiology. 2023 Jan 18; Available from: https://www.sciencedirect.com/science/article/pii/S1047279723000182

This report presents a new estimate of the prevalence of autism among adults aged 18 years and over. This was derived using data from the 2007 Adult Psychiatric Morbidity Survey (APMS 2007) in combination with data from a new study of the prevalence of autism among adults with learning disabilities, who are a key group to study because they could not take part in the APMS 2007 and have been found to have an increased risk of autism. The study was based on adults with learning disabilities living in private households and communal care establishments in Leicestershire, Lambeth and Sheffield. Whilst the study comprised a relatively small sample with limited geographical coverage and did not include the institutional population, it did include two non-mutually exclusive populations (people in communal care establishments and people with learning disabilities) which were not covered by the APMS 2007. The study demonstrates that autism is common among people with a learning disability and, in taking these into account, at 1.1 per cent nationally is slightly higher than the previous estimate of 1.0 per cent in the APMS 2007. Sensitivity analysis showed that the estimates for national prevalence produced by this study were relatively insensitive to inaccuracies caused by the limitations.

The prevalence rate of autism spectrum disorder among four-year-old children in Missouri was around 24.8 per 1,000 children in 2022. Autism spectrum disorder is a developmental disability characterized by deficits in social communication and interaction as well as repetitive behavior, interest, or activity patterns. This statistic displays the estimated prevalence of autism spectrum disorder among children aged four years in select U.S. states in 2022.

Input datasets on Ohio Birth and Autism will not be made accessible to the public due to the fact that they include individual-level data with PII. Output data are all available in tabulated form within the published manuscript. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Input data can be obtained from Applications from owners of the data (Children's Hospital and Ohio Department of Health). The tabulated output data is found in the manuscript. Format: Input datasets on Ohio Birth and Autism will not be made accessible to the public due to the fact that they include individual-level data with PII. Output data are all available in tabulated form within the published manuscript (e.g., results of regression models, measures of central tendency, population characteristics, etc.). This dataset is associated with the following publication: Kaufman, J., M. Wright, G. Rice, N. Connolly, K. Bowers, and J. Anixt. AMBIENT OZONE AND FINE PARTICULATE MATTER EXPOSURES AND AUTISM SPECTRUM DISORDER IN METROPOLITAN CINCINNATI, OHIO. ENVIRONMENTAL RESEARCH. Elsevier B.V., Amsterdam, NETHERLANDS, 171: 218-227, (2019).

This data collection is associated with a large population-based twin study of gender differences in autism. The data were collected from 2016-2019 from a sample population based in the UK. All participants were aged between 20-24 years of age at the time of data collection. The data deposited in this collection are taken from in-home assessments and accompanying questionnaires completed by the twins. The collection includes data from Autism Diagnostic Observation Schedule -2 assessments, the Social Responsiveness Scale (2nd edition) (a measure of autism traits), WASI IQ assessments, Strengths and Difficulties Questionnaire total domain scores (a measure of aspects of mental health) and the WHOQoL Bref (a measure of quality of life). Also included in the collection are demographic information for the participants including sex, age, zygosity and a grouping variable to indicate whether they were included in the study’s diagnosed, high trait or co-twin sample groups.

The prevalence rate of autism spectrum disorder among children aged eight years in Missouri was **** per 1,000 children in 2010. In 2022, this rate was estimated to be **** per 1,000 eight-year-olds. Autism spectrum disorder is a developmental disability characterized by deficits in social communication and interaction as well as repetitive behavior, interest, or activity patterns. This statistic displays the estimated prevalence of autism spectrum disorder among children aged 8 years in select U.S. states from 2010 to 2022.

Snapshot img

Autism Spectrum Disorder Therapeutics Market Size 2025-2029

The autism spectrum disorder therapeutics market size is forecast to increase by USD 825.9 million at a CAGR of 6.9% between 2024 and 2029.

The Autism Spectrum Disorder (ASD) therapeutics market is experiencing significant growth due to the increasing prevalence of ASD, with an estimated 1 in 54 children diagnosed with the disorder in the United States alone. This trend is driven by heightened awareness, improved diagnostic tools, and expanding healthcare coverage. Another key driver is the growing interest in personalized medicine for ASD treatment, as researchers explore the potential of precision therapies tailored to individual patients' unique genetic and environmental factors. This market is driven by the growing awareness and early diagnosis of ASD, fueled by increasing public education and advancements in genetic research and genetic testing. 
Additionally, the complex nature of ASD and its diverse symptoms necessitate a multidisciplinary approach, adding to the development challenges and costs. Companies seeking to capitalize on market opportunities must navigate these regulatory hurdles and collaborate with various stakeholders to develop effective, personalized treatment solutions for the ASD population. However, the market faces several challenges. However, the market is also subject to stringent regulations, ensuring the safety and efficacy of therapeutic interventions and medical technologies.

What will be the Size of the Autism Spectrum Disorder Therapeutics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The Autism Spectrum Disorder (ASD) therapeutics market encompasses a range of interventions addressing the neurological underpinnings and diverse manifestations of this complex condition. Cognitive impairment, executive function deficits, emotional regulation skills, and sensory processing disorders are common challenges for individuals with ASD. Sleep hygiene practices and mental health services are essential components of holistic care, with growing emphasis on community integration and supported employment. Pharmacological treatments, including those targeting anxiety reduction and depression management, are used in conjunction with behavioral interventions such as Applied Behavior Analysis (ABA) therapy methods and communication intervention. Genetic screening and diagnostic tools are crucial for early childhood intervention, while teacher training and inclusionary educational practices foster a more comprehensive understanding of ASD subtypes.

Neuronal circuit dysfunction and immune system involvement are areas of ongoing research, with brain imaging techniques providing valuable insights into the condition's neurological basis. Self-harm prevention strategies and adaptive behavior skills training are essential for promoting independence and improving quality of life. CBT for autism and vocational rehabilitation programs further enhance the overall therapeutic landscape. Autism prevalence rates continue to rise, necessitating a multifaceted, evidence-based approach to addressing the diverse needs of this population. Antipsychotic drugs, including bipolar disorder therapeutics, are commonly prescribed for managing aggressive behaviors, mood stabilization, and anxiety in ASD patients.

How is this Autism Spectrum Disorder Therapeutics Industry segmented?

The autism spectrum disorder therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Retail pharmacy
  Hospital pharmacy
  Online pharmacy


Type

  Stimulants
  Selective serotonin reuptake inhibitors
  Antipsychotic drugs
  Sleep medications
  Others


Application

  Autistic disorder
  Asperger syndrome
  Pervasive developmental disorder
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    Spain
    UK


  APAC

    China
    India
    Japan


  Rest of World (ROW)

By Distribution Channel Insights

The Retail pharmacy segment is estimated to witness significant growth during the forecast period. The autism spectrum disorder (ASD) therapeutics market is experiencing significant growth due to increasing awareness and advancements in novel treatment approaches. Cognitive behavioral therapy, occupational therapy interventions, and neurobiological mechanisms form the foundation of many interventions, addressing social skills training, communication deficits, sensory integration, and emotional regulation. Family therapy approaches and educational support services are essential

This scoping review aims to identify the incidence and prevalence of autism spectrum disorder in brazilian children. The search included studies published in the following databases: PUBMED, SCOPUS, CINAHL and LILACS correlating the descriptors Prevalence, Incidence, Diagnosis, Epidemiology, Autistic Disorder, Autism Spectrum Disorder, Asperger Syndrome, Pervasive Child Development Disorders, Brazil and synonymous terms, with the objective of finding scientific evidence to answer the research question proposed in the present study. To identify the search terms, the controlled health vocabularies DeCs (Health Sciences Descriptors) and MeSH (Medical Subject Headings) were consulted. No date, language and/or study design filters were applied. The search strategy development process met the recommendations of the Peer Review of Electronic Search Strategies (PRESS). A descriptive summary of the types of studies carried out, year of study, age range of children, instruments used for diagnosis, incidence, prevalence, location of the study will be presented.

Financial overview and grant giving statistics of Autism Spectrum Research Alliance

Autism spectrum disorder (ASD) prevalence per 1,000 children (with 95% confidence interval) for 2010 Georgia Autism and Developmental Disabilities Monitoring Network site: comparison between published and algorithm-derived estimates.

The global Autism Spectrum Disorder (ASD) Screening Service market size was valued at USD 3.2 billion in 2023 and is projected to reach USD 5.6 billion by 2033, growing at a CAGR of 5.9% during the forecast period. The rising prevalence of ASD, increasing awareness about early diagnosis and intervention, and technological advancements are driving the growth of the market. The increasing number of government initiatives and reimbursement policies for ASD screening are also contributing to the market growth. In terms of segmentation, the child application segment is expected to dominate the market, owing to the higher prevalence of ASD in children. The developmental screening service segment is projected to witness significant growth due to the increasing demand for early diagnosis and intervention. North America is currently the largest regional market, followed by Europe and Asia-Pacific. The market in North America is driven by the high prevalence of ASD, well-established healthcare infrastructure, and favorable reimbursement policies. However, the market in Asia-Pacific is expected to grow at the fastest rate during the forecast period, due to the increasing awareness about ASD and rising healthcare spending. The Autism Spectrum Disorder Screening Service market is a rapidly growing industry, driven by the increasing prevalence of autism spectrum disorder (ASD) and the need for early diagnosis and intervention. The market is expected to reach $1.5 billion by 2025, according to a recent report by Grand View Research.